Lexicon Pharmaceuticals Stock (NASDAQ: LXRX)

Lexicon Pharmaceuticals

LEXICON PHARMACEUTICALS INC

Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.

Wall Street US stocks

Analyst Color

Asia

Earnings

Earnings Beats

Earnings Misses

Equities

Government

Macro Economic Events

Macro Notification

Market Summary

News

Regulations

Bonds

Broad U.S. Equity ETFs

Guidance

Emerging Markets

Eurozone

Futures

Commodities

Forex

Treasuries

Economics

Federal Reserve

Pre-Market Outlook

Markets

Analyst Ratings

ETFs

General

LOAR

LXRX

PRGS

U.S. stock futures fell on Monday after three consecutive days of decline on Friday. Futures of benchmark indices were lower in premarket.

US Stocks Likely To Open Lower After 3-Day Fall: &#39;Equity Drawdown Probability Hasn&#39;t Peaked Yet,&#39; Says Goldman Sachs Analyst

Some Speculative Stocks Can Pay Off

Small Cap

LWLG

As uncertainties surrounding trade policies, fresh recession fears, and persistent inflation kept the markets on tenterhooks throughout the past week, a handful of small-caps defied the odds by posting significant gains. 

While Wall Street Panicked, These 3 Hidden Small-Caps Exploded Last Week — One Surging A Jaw-Dropping 60%

nasdaq shutter

Intraday Update

Trading Ideas

DBVT

MIST

PRTG

WOLF

XTIA

Nasdaq Down 100 Points; Federal Reserve&#39;s Favorite Inflation Gauge Increases More Than Expected

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals Inc

Press Releases

Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

Health Care

Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

Emerging Tech Quartet – PRSO, LXRX, PRTG, RNAZ – Drive Breakthroughs Across Defense, Obesity, Oncology, and RNA Therapeutics

Lexicon Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

PRSO

RNAZ

Abeona Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Amarin Corp

Anika Therapeutics

Annexon

Candel Therapeutics

Cidara Therapeutics

Cardiff Oncology

Cargo Therapeutics

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Foghorn Therapeutics

Gossamer Bio

Humacyte

Immutep Limited - American Depositary Shares

Immutep

Inhibrx Biosciences

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

ITeos Therapeutics

Monopar Therapeutics

Nuvectis Pharma

Ocugen

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

AVITA Medical

Solid Biosciences

Tevogen Bio Holdings

Y-mAbs Therapeutics

HC Wainwright & Co.

Piper Sandler

Leerink Partners

Citigroup

Comments

Lexicon Pharmaceuticals

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga